Cargando…
ALK in Neuroblastoma: Biological and Therapeutic Implications
Neuroblastoma (NB) is the most common and deadly solid tumour in children. Despite the development of new treatment options for high-risk NB, over half of patients relapse and five-year survival remains at 40–50%. Therefore, novel treatment strategies aimed at providing long-term disease remission a...
Autores principales: | Trigg, Ricky M., Turner, Suzanne D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5923368/ https://www.ncbi.nlm.nih.gov/pubmed/29642598 http://dx.doi.org/10.3390/cancers10040113 |
Ejemplares similares
-
Opportunities and challenges of circulating biomarkers in neuroblastoma
por: Trigg, Ricky M., et al.
Publicado: (2019) -
Diagnostic accuracy of circulating-free DNA for the determination of MYCN amplification status in advanced-stage neuroblastoma: a systematic review and meta-analysis
por: Trigg, Ricky M., et al.
Publicado: (2020) -
The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status
por: Trigg, Ricky M., et al.
Publicado: (2019) -
Therapeutic Targeting of the Anaplastic Lymphoma Kinase (ALK) in Neuroblastoma—A Comprehensive Update
por: Brenner, Annette K., et al.
Publicado: (2021) -
Targeting MYCN and ALK in resistant and relapsing neuroblastoma
por: Tucker, Elizabeth R, et al.
Publicado: (2019)